Watch RCKT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
60
WATCH · insiders 50, shorts 69
Insiders, 90 days
−$10K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $423.7MP/E —DIV YIELD —FCF YIELD -40.21%REV TTM $0NET INCOME −$17.3MNET CASH —52W 2.60 – 5.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$46.9M | $123.2M | — | 1.08 | −$39.6M | $8K | −$39.6M | Aug 10 |
| Q1 2026 · Mar 31 | $0 | — | — | −$48.5M | −$47.6M | — | -0.42 | −$45.4M | $93K | −$45.5M | Aug 10 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$44M | −$42.5M | — | -0.38 | −$34.8M | $80K | −$34.9M | Feb 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$52.2M | −$50.3M | — | -0.45 | −$50.4M | −$54K | −$50.4M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$71.1M | −$68.9M | — | -0.62 | −$49M | $50K | −$49M | Aug 10 |
| Q1 2025 · Mar 31 | $0 | — | — | −$64.4M | −$61.3M | — | -0.56 | −$55.8M | $364K | −$56.2M | Aug 10 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$62.7M | −$60.3M | — | -0.62 | −$46.9M | $309K | −$47.3M | Feb 26 |
| Q3 2024 · Sep 30 | $0 | — | — | −$69.4M | −$66.7M | — | -0.71 | −$52.1M | $1.6M | −$53.7M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$73.7M | −$69.6M | — | -0.74 | −$53.8M | $1.9M | −$55.8M | Nov 6 |
| Q1 2024 · Mar 31 | $0 | — | — | −$67.4M | −$62.1M | — | -0.66 | −$56.9M | $2M | −$58.9M | Nov 6 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$63.3M | −$59.7M | — | -0.62 | −$29.3M | $4.6M | −$34M | Feb 27 |
| Q3 2023 · Sep 30 | $0 | — | — | −$65.4M | −$61.9M | — | -0.75 | −$57.1M | $4.7M | −$61.8M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$231.7M | −$223.1M | — | -2.01 | −$190M | $440K | −$190.5M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$273.2M | −$258.7M | — | -2.73 | −$209.7M | $5.9M | −$215.6M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$259.7M | −$245.6M | — | -2.92 | −$194.9M | $16.4M | −$211.4M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$224.3M | −$221.9M | — | -3.26 | −$178.1M | $8.4M | −$186.5M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$167.2M | −$169.1M | — | -2.67 | −$121.2M | $7.6M | −$128.8M | $0 | — |
| FY2020 · to Dec 31 | $0 | — | −$134.3M | −$139.7M | — | -2.52 | −$74.6M | $20.6M | −$95.2M | $72K | — |
Every number comes from ROCKET PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.